国际妇产科学杂志

国际妇产科学杂志 ›› 2014, Vol. 41 ›› Issue (1): 52-56.

• 综述 • 上一篇    下一篇

二甲双胍与卵巢癌关系的研究进展

朱杰，孙红   

  1. 200011 上海，复旦大学附属妇产科医院
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2014-02-15 发布日期:2014-02-15
  • 通讯作者: 孙红

The Relationship between Metformin and Ovarian Cancer

ZHU Jie，SUN Hong   

  1. The Relationship between Metformin and Ovarian Cancer
  • Received:1900-01-01 Revised:1900-01-01 Published:2014-02-15 Online:2014-02-15
  • Contact: SUN Hong

PDF (PC)

5264

被引次数

12

摘要： 二甲双胍是目前治疗2型糖尿病的一线口服药。除了有效发挥降糖作用外，流行病学研究和动物实验表明，二甲双胍还具有抗卵巢癌等抗肿瘤的作用，其可以降低卵巢癌发病率、提高患者生存率。二甲双胍发挥这些作用的机制尚不确定，可能包括降低空腹血糖和胰岛素水平、激活AMP活化蛋白激酶（AMPK）通路、抑制线粒体呼吸链复合物Ⅰ、导致细胞周期停滞、选择性杀灭卵巢癌干细胞、促进细胞凋亡等。但在设计最佳的临床试验之前，有很多关键问题亟待解决。今后仍需要进一步的实验室研究以及大样本、前瞻性的临床试验来阐述二甲双胍的抗卵巢癌作用。

关键词: 二甲双胍, 卵巢肿瘤, 糖尿病, 2型, 机制, AMP活化蛋白激酶

Abstract: Metformin is the first-line oral drug for type 2 diabetes currently. While it plays an important role as an anti-diabetes drug，the anti-neoplastic activity of metformin has also been reported in epidemiological and animal studies in many cancers such as ovarian cancer，as it could reduce the risk of ovarian cancer and improve the survival rate. The mechanisms by which metformin exerts these effects are unknown, which may include decreasing fasting glucose and insulin level，activating the AMP-activated protein kinase （AMPK），inhibiting the mitochondrial complexⅠ，inducing cell cycle arrest，selectively killing the ovarian cancer stem cell and promoting apoptosis，etc. Many key problems need to be solved before the design of best clinical trials. Further laboratory investigation and large population prospective clinical trials are required to elucidate the mechanisms of metformin anti-neoplastic actions in ovarian cancer.

Key words: Metformin, Ovarian neoplasms, Diabetes mellitus, type 2, Mechanism, AMP-activated protein kinase